US Edition
Consensus study on the use of SGLT2 inhibitors in people with diabetes-related foot disease – EDFN
Summary by edfn.org
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Consensus study on the use of SGLT2 inhibitors in people with diabetes-related foot disease – EDFN
A consensus study has found “relative confidence” of clinicians in prescribing SGLT2 inhibitors to those with diabetes-related foot disease, provided that patients do not have a current ulcer and that canagliflozin is not prescribed. The study team, which included researchers from the Diabetes Research Centre in Leicester, set out to generate expert consensus-based clinical recommendations on the use of SGLT2 inhibitors in those with diabetes an…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
